Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATL001 |
Synonyms | |
Therapy Description |
ATL001 are personalized patient-derived tumor infiltrating lymphocytes that target tumor neoantigens, which may result in the induction of an antitumor immune response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATL001 | ATL 001|ATL-001 | ATL001 are personalized patient-derived tumor infiltrating lymphocytes that target tumor neoantigens, which may result in the induction of an antitumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03997474 | Phase Ib/II | ATL001 + Nivolumab ATL001 | ATL001 in Patients With Metastatic or Recurrent Melanoma | Terminated | GBR | ESP | 0 |
NCT04032847 | Phase Ib/II | ATL001 + Pembrolizumab ATL001 | ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | Terminated | USA | GBR | FRA | ESP | DEU | 0 |